Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Background Tuberculosis regimens that are shorter and simpler than the current 6-month
daily regimen are needed. Methods We randomly assigned patients with newly diagnosed, …

mRNA-1273 Vaccine Efficacy against the Delta Variant Participants who had received
placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label …

Methods: This phase II, randomized clinical trial was conducted to evaluate the antibody
and cell-mediated responses to a trivalent influenza vaccine administered without adjuvant (TIV…

BackgroundFollowing emergency use authorization in December 2020, the Coronavirus
Efficacy (COVE) trial was amended to an open-label phase, where participants were unblinded …

Background: A/H5N1 influenza virus has significant pandemic potential, and vaccination is
the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter study …

… The authors would also like to thank Heather Clouting for her contribution and leadership
in … Heather, E.; Shimmon, R.; McDonagh, AM Organic impurity profiling of 3,4-…

The International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB)
say that cumbersome regulatory procedures for clinical trials are stalling progress in the …

… Clouting , … Clouting … Many thanks also to Fabrizio Lemma, Jon Rogers, Matthew
Stokes, Monique Toszeghy and Heather Wearing for various parts of the laboratory work. …

Background A/H5N1 influenza viruses have high pandemic potential; consequently, vaccines
need to be produced rapidly. MF59® adjuvant reduces the antigen required per dose, …